These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 23962923)

  • 21. Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.
    Doecke JD; Rembach A; Villemagne VL; Varghese S; Rainey-Smith S; Sarros S; Evered LA; Fowler CJ; Pertile KK; Rumble RL; Trounson B; Taddei K; Laws SM; Macaulay SL; Bush AI; Ellis KA; Martins R; Ames D; Silbert B; Vanderstichele H; Masters CL; Darby DG; Li QX; Collins S;
    J Alzheimers Dis; 2018; 61(1):169-183. PubMed ID: 29171991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment.
    Mattsson N; Portelius E; Rolstad S; Gustavsson M; Andreasson U; Stridsberg M; Wallin A; Blennow K; Zetterberg H
    J Alzheimers Dis; 2012; 30(4):767-78. PubMed ID: 22475796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced Slow-Wave Sleep Is Associated with High Cerebrospinal Fluid Aβ42 Levels in Cognitively Normal Elderly.
    Varga AW; Wohlleber ME; Giménez S; Romero S; Alonso JF; Ducca EL; Kam K; Lewis C; Tanzi EB; Tweardy S; Kishi A; Parekh A; Fischer E; Gumb T; Alcolea D; Fortea J; Lleó A; Blennow K; Zetterberg H; Mosconi L; Glodzik L; Pirraglia E; Burschtin OE; de Leon MJ; Rapoport DM; Lu SE; Ayappa I; Osorio RS
    Sleep; 2016 Nov; 39(11):2041-2048. PubMed ID: 27568802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease.
    Vlassenko AG; McCue L; Jasielec MS; Su Y; Gordon BA; Xiong C; Holtzman DM; Benzinger TL; Morris JC; Fagan AM
    Ann Neurol; 2016 Sep; 80(3):379-87. PubMed ID: 27398953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease.
    Gomar JJ; Conejero-Goldberg C; Davies P; Goldberg TE;
    J Alzheimers Dis; 2016; 51(4):1085-97. PubMed ID: 26967213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Soluble BACE-1 Activity and sAβPPβ Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort.
    Savage MJ; Holder DJ; Wu G; Kaplow J; Siuciak JA; Potter WZ;
    J Alzheimers Dis; 2015; 46(2):431-40. PubMed ID: 25790831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
    J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerebrospinal Fluid Changes in the Renin-Angiotensin System in Alzheimer's Disease.
    Kehoe PG; Al Mulhim N; Zetterberg H; Blennow K; Miners JS
    J Alzheimers Dis; 2019; 72(2):525-535. PubMed ID: 31594235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.
    Fagan AM; Shaw LM; Xiong C; Vanderstichele H; Mintun MA; Trojanowski JQ; Coart E; Morris JC; Holtzman DM
    Arch Neurol; 2011 Sep; 68(9):1137-44. PubMed ID: 21555603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reappraisal of Aβ40 and Aβ42 Peptides Measurements in Cerebrospinal Fluid of Patients with Alzheimer's Disease.
    Fiorini M; Bongianni M; Benedetti MD; Monaco S; Zanusso G
    J Alzheimers Dis; 2018; 66(1):219-227. PubMed ID: 30282368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
    Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease.
    Irwin DJ; Fedler J; Coffey CS; Caspell-Garcia C; Kang JH; Simuni T; Foroud T; Toga AW; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Weintraub D; Mollenhauer B; Galasko DR; Siderowf A; Marek K; Trojanowski JQ; Shaw LM;
    Ann Neurol; 2020 Sep; 88(3):574-587. PubMed ID: 32542885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid.
    Landau SM; Lu M; Joshi AD; Pontecorvo M; Mintun MA; Trojanowski JQ; Shaw LM; Jagust WJ;
    Ann Neurol; 2013 Dec; 74(6):826-36. PubMed ID: 23536396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ganoderic Acid A Promotes Amyloid-β Clearance (In Vitro) and Ameliorates Cognitive Deficiency in Alzheimer's Disease (Mouse Model) through Autophagy Induced by Activating Axl.
    Qi LF; Liu S; Liu YC; Li P; Xu X
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34074054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease.
    Almeida RP; Schultz SA; Austin BP; Boots EA; Dowling NM; Gleason CE; Bendlin BB; Sager MA; Hermann BP; Zetterberg H; Carlsson CM; Johnson SC; Asthana S; Okonkwo OC
    JAMA Neurol; 2015 Jun; 72(6):699-706. PubMed ID: 25893879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beta-amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease.
    Andreasen N; Blennow K
    Peptides; 2002 Jul; 23(7):1205-14. PubMed ID: 12128078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of clusterin in amyloid-β-associated neurodegeneration.
    Desikan RS; Thompson WK; Holland D; Hess CP; Brewer JB; Zetterberg H; Blennow K; Andreassen OA; McEvoy LK; Hyman BT; Dale AM;
    JAMA Neurol; 2014 Feb; 71(2):180-7. PubMed ID: 24378367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrospinal fluid Abeta40 and Abeta42: natural course and clinical usefulness.
    Shoji M
    Front Biosci; 2002 Apr; 7():d997-1006. PubMed ID: 11897565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.